Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

A clinical trial that looked into the effects of the new pill plus fulvestrant, a hormone therapy, found that the treatment ...

The National Institute for Health and Care Excellence has now approved capivasertib for use on the NHS - we look at who could ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

Several recent Atavistik Bio Inc. patents describe substituted aminopyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors, particularly AKT1 (E17K mutant) reported ...

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

That may be because the non-biomarker group in the study included quite a high proportion of untested patients in whom PIK3CA/AKT1/PTEN status was unknown. Mutations in PIK3CA, AKT1, and ...

Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival Eligible patients had AKT1 E17K–mutated metastatic tumors that progressed with standard ...